BIOMAT Database Logo BIOMAT Database Logo

Protein-C concentrate for meningococcal purpura fulminans. 1998

W Kreuz, and A Veldman, and C Escuriola-Ettingshausen, and W Schneider, and T Beeg

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008585 Meningitis, Meningococcal A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8) Meningitis, Neisseria,Neisseria Meningitis,Meningitis, Meningococcal, Serogroup A,Meningitis, Meningococcal, Serogroup B,Meningitis, Meningococcal, Serogroup C,Meningitis, Meningococcal, Serogroup W-135,Meningitis, Meningococcal, Serogroup W135,Meningitis, Meningococcal, Serogroup Y,Meningitis, Meningococcic,Meningococcal Meningitis, Serogroup A,Meningococcal Meningitis, Serogroup B,Meningococcal Meningitis, Serogroup C,Meningococcal Meningitis, Serogroup W-135,Meningococcal Meningitis, Serogroup W135,Meningococcal Meningitis, Serogroup Y,Serogroup A Meningococcal Meningitis,Serogroup B Meningococcal Meningitis,Serogroup C Meningococcal Meningitis,Serogroup W-135, Meningococcal Meningitis,Serogroup W135, Meningococcal Meningitis,Serogroup Y, Meningococcal Meningitis,Meningococcal Meningitis,Meningococcal Meningitis, Serogroup W 135,Neisseria Meningitides,Serogroup W 135, Meningococcal Meningitis
D011486 Protein C A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
D011695 IgA Vasculitis A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections. Allergic Purpura,Anaphylactoid Purpura,Henoch Purpura,Henoch-Schoenlein Purpura,Purpura Hemorrhagica,Purpura, Nonthrombocytopenic,Purpura, Schoenlein-Henoch,Rheumatoid Purpura,Schoenlein-Henoch Purpura,Vasculitis, Hemorrhagic,Henoch Schonlein Purpura,Henoch-Schonlein Purpura,Purpura, Nonthrombopenic,Purpura, Schonlein-Henoch,Hemorrhagic Vasculitis,Hemorrhagica, Purpura,Henoch Schoenlein Purpura,Henoch Schonlein Purpuras,Henoch-Schonlein Purpuras,Nonthrombocytopenic Purpura,Nonthrombopenic Purpura,Nonthrombopenic Purpuras,Purpura, Allergic,Purpura, Anaphylactoid,Purpura, Henoch,Purpura, Henoch Schonlein,Purpura, Henoch-Schoenlein,Purpura, Henoch-Schonlein,Purpura, Rheumatoid,Purpura, Schoenlein Henoch,Purpura, Schonlein Henoch,Purpuras, Henoch Schonlein,Purpuras, Henoch-Schonlein,Purpuras, Nonthrombopenic,Purpuras, Schonlein-Henoch,Schoenlein Henoch Purpura,Schonlein Purpura, Henoch,Schonlein Purpuras, Henoch,Schonlein-Henoch Purpura,Schonlein-Henoch Purpuras,Vasculitis, IgA
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D012772 Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status. Endotoxin Shock,Septic Shock,Shock, Endotoxic,Shock, Toxic,Toxic Shock,Toxic Shock Syndrome,Endotoxin Shocks,Shock Syndrome, Toxic,Shock, Endotoxin,Shocks, Endotoxin,Toxic Shock Syndromes

Related Publications

W Kreuz, and A Veldman, and C Escuriola-Ettingshausen, and W Schneider, and T Beeg
Protein-C concentrate for meningococcal purpura fulminans.
March 1998, Lancet (London, England),
W Kreuz, and A Veldman, and C Escuriola-Ettingshausen, and W Schneider, and T Beeg
Protein-C concentrate for meningococcal purpura fulminans.
March 1998, Lancet (London, England),
W Kreuz, and A Veldman, and C Escuriola-Ettingshausen, and W Schneider, and T Beeg
Protein-C concentrate for meningococcal purpura fulminans.
March 1998, Lancet (London, England),
W Kreuz, and A Veldman, and C Escuriola-Ettingshausen, and W Schneider, and T Beeg
Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans.
January 1999, Seminars in thrombosis and hemostasis,
W Kreuz, and A Veldman, and C Escuriola-Ettingshausen, and W Schneider, and T Beeg
Treatment of purpura fulminans in meningococcemia with protein C concentrate.
April 1995, The Journal of pediatrics,
W Kreuz, and A Veldman, and C Escuriola-Ettingshausen, and W Schneider, and T Beeg
[Meningococcal purpura fulminans].
April 2003, Presse medicale (Paris, France : 1983),
W Kreuz, and A Veldman, and C Escuriola-Ettingshausen, and W Schneider, and T Beeg
[Meningococcal purpura fulminans].
December 2008, Revista espanola de anestesiologia y reanimacion,
W Kreuz, and A Veldman, and C Escuriola-Ettingshausen, and W Schneider, and T Beeg
Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency.
January 2004, Journal of pediatric hematology/oncology,
W Kreuz, and A Veldman, and C Escuriola-Ettingshausen, and W Schneider, and T Beeg
Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate.
January 1996, European journal of pediatrics,
W Kreuz, and A Veldman, and C Escuriola-Ettingshausen, and W Schneider, and T Beeg
[Meningococcal purpura fulminans: treatment with recombinant protein C activator in 3 cases].
October 2007, Revista espanola de anestesiologia y reanimacion,
Copied contents to your clipboard!